{"analyses":[{"ciLowerLimit":"0.552","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.860","estimateComment":"Log-rank test stratified by:\\* Region (Asia vs Non-Asia), \\* Number of organs with metastatic sites (0 to 2 vs \\>= 3), \\* Prior gastrectomy (Yes or No)","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0005","paramType":"Hazard Ratio (HR)","paramValue":"0.689","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.26","upperLimit":"8.84","value":"8.21"},{"groupId":"OG001","lowerLimit":"6.14","upperLimit":"8.08","value":"6.80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"253"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of randomization until the date of radiological progressive disease (PD) (per Response Evaluation Criteria in Solid Tumors \\[RECIST\\] 1.1 by independent review committee \\[IRC\\]) or death from any cause, whichever was earliest. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan-Meier estimates was used.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an intravenous (IV) infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 milligrams per square meter (mg/m\\^2) on cycle 1 day 1 (C1D1) followed by subsequent doses of 600 mg/m\\^2 every 3 weeks starting from C2D1 until participant met study treatment discontinuation criteria. Participants also received up to 8 treatments of capecitabine and oxaliplatin (CAPOX) treatment. Oxaliplatin was administered 130 mg/m\\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\\^2 twice daily (bid) on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21","id":"OG000","title":"CAPOX+ Zolbetuximab"},{"description":"Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C2D1 until participant met study treatment discontinuation criteria. Participants also received up to 8 treatments of CAPOX. Oxaliplatin was administered 130 mg/m\\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\\^2 bid on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21 days.","id":"OG001","title":"CAPOX+ Placebo"}],"paramType":"MEDIAN","populationDescription":"FAS","reportingStatus":"POSTED","timeFrame":"From the date of randomization until 61 months and 12 days","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}